PET/CT Imaging in Cardiac Sarcoidosis

Year 2024, Volume: 4 Issue: 3, 46 - 52, 14.01.2025

Adil Gümüş , Pınar Pelin Özcan , Zehra Pınar Koç , Mahmut Süleymanoğlu , Zeynep Selcan Sağlam

https://doi.org/10.71286/moi.1607134

Abstract

Sarcoidosis is a systemic granulomatous disease of unknown cause. The most commonly affected structures are the thoracic lymph nodes and the lungs, but any organ can be involved . In sarcoidosis, the heart can be affected both due to lung involvement and direct disease involvement. Clinically detected cardiac involvement is around 5%; However higher rates are reported in autopsy series. Endomyocardial biopsy, which is the definitive diagnostic method, is difficult and has low diagnostic value. Effective and reliable advanced cardiac imaging methods are needed in cardiac sarcoidosis . As well as the diagnosis of cardiac sarcoidosis, it is also important to determine disease activation, determine the treatment strategy, evaluate the severity, estimate the prognosis, and adjust steroid therapy . The most commonly used molecular imaging method in clinical practice for these purposes is Fluorodeoxyglucose (FDG) PET/CT imaging labeled with Fluorine-18 (F-18). Increased uptake in the myocardium on F-18 FDG PET/CT imaging is considered an important finding reflecting the activity of inflammation in cardiac sarcoidosis. In this report, two patients whose sarcoidosis diagnosis was confirmed histopathologically and who underwent PET CT examination due to cardiac sarcoidosis in our department are presented.

Keywords

cardiac sarkoidosis, PET, CT, Imaging

References

• Handa, T., Nagai, S., Miki, S., Fushimi, Y., Ohta, K., Mishima, M., & Izumi, T. (2006). Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest, 129(5), 1246–1252. https://doi.org/10.1378/chest.129.5.1246
• Musellim, B., Kumbasar, O. O., Ongen, G., Cetinkaya, E., Turker, H., Uzaslan, E., Yenturk, E., Uzun, O., Saglam, L., Celik, G., Okumus, G., Annakkaya, A. N., Altiay, G., Tabak, L., Sakar, A., Kiter, G., Erturan, S., Turktas, H., Yalniz, E., Akkoclu, A., … Uzel, I. (2009). Epidemiological features of Turkish patients with sarcoidosis. Respiratory medicine, 103(6), 907–912. https://doi.org/10.1016/j.rmed.2008.12.011
• Fahy, G. J., Marwick, T., McCreery, C. J., Quigley, P. J., & Maurer, B. J. (1996). Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest, 109(1), 62–66. https://doi.org/10.1378/chest.109.1.62
• Mikami, R., Sekiguchi, M., Ryuzin, Y., Kobayashi, F., Hiraga, Y., Shimada, Y., Mochizuki, I., Kobayashi, T., Tamura, S., & Hosoda, Y. (1986). Changes in the peripheral vasculature of various organs in patients with sarcoidosis--possible role of microangiopathy. Heart and vessels, 2(3), 129–139. https://doi.org/10.1007/BF02128138
• Koiwa, H., Tsujino, I., Ohira, H., Yoshinaga, K., Otsuka, N., & Nishimura, M. (2010). Images in cardiovascular medicine: Imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography: an autopsy case. Circulation, 122(5), 535–536. https://doi.org/10.1161/CIRCULATIONAHA.110.952184.
• Grutter JC, Drent M, van den Bosch JMM. Sarcoidosis. Eur Respir Mon 2009;46: 126-154.
• Yazaki, Y., Isobe, M., Hiroe, M., Morimoto, S., Hiramitsu, S., Nakano, T., Izumi, T., Sekiguchi, M., & Central Japan Heart Study Group (2001). Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. The American journal of cardiology, 88(9), 1006–1010. https://doi.org/10.1016/s0002-9149(01)01978-6
• Fleming, H. A., & Bailey, S. M. (1986). The prognosis of sarcoid heart disease in the United Kingdom. Annals of the New York Academy of Sciences, 465, 543–550. https://doi.org/10.1111/j.1749-6632.1986.tb18531.x
• Vignaux, O., Dhote, R., Duboc, D., Blanche, P., Dusser, D., Weber, S., & Legmann, P. (2002). Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest, 122(6), 1895–1901. https://doi.org/10.1378/chest.122.6.1895
• Shammas, R. L., & Movahed, A. (1993). Sarcoidosis of the heart. Clinical cardiology, 16(6), 462–472. https://doi.org/10.1002/clc.4960160603
• Bargout, R., & Kelly, R. F. (2004). Sarcoid heart disease: clinical course and treatment. International journal of cardiology, 97(2), 173–182. https://doi.org/10.1016/j.ijcard.2003.07.024
• Yoshinaga K, Miyagawa M, Kiso K, Ishida Y. Japanese Guidelines for Cardiac Sarcoidosis. Annals of Nuclear Cardiology 2017;3:121-124.
• Mc Ardle, B. A., Leung, E., Ohira, H., Cocker, M. S., deKemp, R. A., DaSilva, J., Birnie, D., Beanlands, R. S., & Nery, P. B. (2013). The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 20(2), 297–306. https://doi.org/10.1007/s12350-012-9668-9
• Leone, O., Veinot, J. P., Angelini, A., Baandrup, U. T., Basso, C., Berry, G., Bruneval, P., Burke, M., Butany, J., Calabrese, F., d'Amati, G., Edwards, W. D., Fallon, J. T., Fishbein, M. C., Gallagher, P. J., Halushka, M. K., McManus, B., Pucci, A., Rodriguez, E. R., Saffitz, J. E., … Winters, G. L. (2012). 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology, 21(4), 245–274. https://doi.org/10.1016/j.carpath.2011.10.001
• Schatka, I., & Bengel, F. M. (2014). Advanced imaging of cardiac sarcoidosis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(1), 99–106. https://doi.org/10.2967/jnumed.112.115121
• Youssef, G., Leung, E., Mylonas, I., Nery, P., Williams, K., Wisenberg, G., Gulenchyn, K. Y., Dekemp, R. A., Dasilva, J., Birnie, D., Wells, G. A., & Beanlands, R. S. (2012). The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53(2), 241–248. https://doi.org/10.2967/jnumed.111.090662
• Ohira, H., Tsujino, I., Ishimaru, S., Oyama, N., Takei, T., Tsukamoto, E., Miura, M., Sakaue, S., Tamaki, N., & Nishimura, M. (2008). Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. European journal of nuclear medicine and molecular imaging, 35(5), 933–941. https://doi.org/10.1007/s00259-007-0650-8
• Young, L., Sperry, B. W., & Hachamovitch, R. (2017). Update on Treatment in Cardiac Sarcoidosis. Current treatment options in cardiovascular medicine, 19(6), 47. https://doi.org/10.1007/s11936-017-0539-1
• Saraste, A., & Knuuti, J. (2017). PET imaging in heart failure: the role of new tracers. Heart failure reviews, 22(4), 501–511. https://doi.org/10.1007/s10741-017-9620-9
• Chareonthaitawee, P., Bois, J. P., & Gersh, B. J. (2017). Quantitative Assessment of Myocardial Blood Flow in Cardiac Sarcoidosis: A Potential Next Step in the Further Integration of FDG-PET in Imaging Management?. JACC. Cardiovascular imaging, 10(2), 168–170. https://doi.org/10.1016/j.jcmg.2016.10.008
• Sperry, B. W., Tamarappoo, B. K., Oldan, J. D., Javed, O., Culver, D. A., Brunken, R., Cerqueira, M. D., & Hachamovitch, R. (2018). Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18F-FDG PET Scans for Suspected Cardiac Sarcoidosis. JACC. Cardiovascular imaging, 11(2 Pt 2), 336–345. https://doi.org/10.1016/j.jcmg.2017.04.020
• Slart, R. H. J. A., Glaudemans, A. W. J. M., Lancellotti, P., Hyafil, F., Blankstein, R., Schwartz, R. G., Jaber, W. A., Russell, R., Gimelli, A., Rouzet, F., Hacker, M., Gheysens, O., Plein, S., Miller, E. J., Dorbala, S., Donal, E., & Document Reading Group (2018). A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 25(1), 298–319. https://doi.org/10.1007/s12350-017-1043-4
• Subramaniam, R. M., Janowitz, W. R., Johnson, G. B., Lodge, M. A., Parisi, M. T., Ferguson, M. R., Hellinger, J. C., Gladish, G. W., & Gupta, N. K. (2017). ACR-SPR-STR Practice Parameter for the Performance of Cardiac Positron Emission Tomography - Computed Tomography (PET/CT) Imaging. Clinical nuclear medicine, 42(12), 918–927. https://doi.org/10.1097/RLU.0000000000001827
• Lu, Y., Grant, C., Xie, K., & Sweiss, N. J. (2017). Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis. Clinical nuclear medicine, 42(2), 88–94. https://doi.org/10.1097/RLU.0000000000001465
• Patel, D. C., Gunasekaran, S. S., Goettl, C., Sweiss, N. J., & Lu, Y. (2019). FDG PET-CT findings of extra-thoracic sarcoid are associated with cardiac sarcoid: A rationale for using FGD PET-CT for cardiac sarcoid evaluation. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 26(2), 486–492. https://doi.org/10.1007/s12350-017-0962-4
• Ohira, H., Ardle, B. M., deKemp, R. A., Nery, P., Juneau, D., Renaud, J. M., Klein, R., Clarkin, O., MacDonald, K., Leung, E., Nair, G., Beanlands, R., & Birnie, D. (2017). Inter- and Intraobserver Agreement of 18F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 58(8), 1324–1329. https://doi.org/10.2967/jnumed.116.187203